A graduate of the University of Virginia, where he earned his bachelor’s degree in finance, Michael T. Jackson is a former resident of Belvedere, California, and a pioneer in the hedge fund sector. Since moving to Florida from Belvedere, Michael T. Jackson has continued his support of the American Ireland Fund, which is part of the global network of The Ireland Funds.
Established in 1976, The Ireland Funds support and promote organizations and initiatives that foster peace and facilitate higher educational standards and increased cultural understanding in Ireland. To date, The Ireland Funds have distributed more than $550 million in grants to over 3,000 organizations around the world.
In March 2017, The Ireland Funds announced the grant of $100,000 to the Coalition of Irish Immigration Centers in the United States. The grant will be used to fund the center’s direct humanitarian aid program, which provides Irish immigrants access to help with living costs, legal resources, child care, and medical services.
A former Belvedere resident, Michael T. Jackson founded Napa Medical Research Foundation (NMRF) to support research into orthopedic regenerative healing. Now residing in Florida rather than Belvedere, Michael T. Jackson currently serves as the foundation’s chairman of the board. The NMRF has contributed valuable research to a number of conditions, and one of its recent studies focused on Sever’s disease.
First described by Sever in Boston in 1912, Sever’s disease relates to pain in the heel and Achilles’ tendon, and is a common complaint for children between the ages of seven and 12. It is commonly attributed to apophysitis, or inflammation of the apophysis, which is the insertion site for a tendon.
The study conducted by NMRF found that current treatment methods, such as orthotics, casts, and cast-boots, do not prevent over 50 percent of children from having recurring problems. Instead, after examining the benefits of a 12-week exercise program, the study found that symptoms were resolved completely with exercise in as little as two weeks.
The foundation is now working on developing a different protocol for a randomized control group of 10 patients, with the results to be published upon completion. However, the early signs point to the conclusion that previous methods of treating Sever’s disease are inadequate for patient needs, but possible to be improved upon.